| Hematopoietic subsyndrome of acute radiation syndrome
Neulasta vs Neupogen
Side-by-side clinical, coverage, and cost comparison for hematopoietic subsyndrome of acute radiation syndrome.Deep comparison between: Neulasta vs Neupogen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNeupogen has a higher rate of injection site reactions vs Neulasta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Neupogen but not Neulasta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Neulasta
Neupogen
At A Glance
SC injection
Once per chemotherapy cycle
G-CSF (colony-stimulating factor)
SC injection
Daily
G-CSF
Indications
- Febrile Neutropenia
- Hematopoietic subsyndrome of acute radiation syndrome
- Febrile Neutropenia
- Leukemia, Myelocytic, Acute
- Neutropenia
- Severe congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Hematopoietic subsyndrome of acute radiation syndrome
Dosing
Febrile Neutropenia 6 mg SC once per chemotherapy cycle for adults and pediatric patients >=45 kg; weight-based dosing (1.5-4 mg SC) for pediatric patients weighing 10-44 kg; 0.1 mg/kg for those <10 kg. Do not administer between 14 days before and 24 hours after chemotherapy.
Hematopoietic Subsyndrome of Acute Radiation Syndrome Two doses of 6 mg each SC one week apart for adults and pediatric patients >=45 kg; weight-based dosing for pediatric patients <45 kg. Administer first dose as soon as possible after suspected or confirmed exposure to radiation >2 Gy, and second dose one week after.
Febrile Neutropenia, Leukemia, Myelocytic, Acute 5 mcg/kg/day SC injection, short IV infusion (15-30 min), or continuous IV infusion; administer at least 24 hours after cytotoxic chemotherapy.
Neutropenia (bone marrow transplantation) 10 mcg/kg/day IV infusion no longer than 24 hours; administer at least 24 hours after cytotoxic chemotherapy and bone marrow infusion.
Autologous PBPC collection 10 mcg/kg/day SC injection; administer for at least 4 days before first leukapheresis and continue until last leukapheresis.
Severe congenital neutropenia 6 mcg/kg SC injection twice daily.
Cyclic neutropenia, Idiopathic neutropenia 5 mcg/kg SC injection daily.
Hematopoietic subsyndrome of acute radiation syndrome 10 mcg/kg/day SC injection; administer as soon as possible after suspected or confirmed exposure to radiation doses >2 Gy.
Contraindications
- History of serious hypersensitivity reaction to pegfilgrastim or filgrastim, including anaphylaxis
- History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim
Adverse Reactions
Most common (>=5%) Bone pain, pain in extremity
Serious Splenic rupture, acute respiratory distress syndrome, serious hypersensitivity reactions, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, aortitis
Postmarketing Splenic rupture, splenomegaly, ARDS, anaphylaxis, skin rash, urticaria, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, injection site reactions, Sweet's syndrome, cutaneous vasculitis, MDS, AML, aortitis, alveolar hemorrhage
Most common (>=5%) Pyrexia, nausea, fatigue, thrombocytopenia, bone pain, back pain, rash, dizziness, cough, dyspnea, chest pain, arthralgia
Serious Splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, thrombocytopenia, leukocytosis, cutaneous vasculitis, aortitis
Postmarketing Splenic rupture, splenomegaly, anaphylaxis, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, leukocytosis, cutaneous vasculitis, Sweet's syndrome, decreased bone density and osteoporosis, myelodysplastic syndrome, acute myeloid leukemia, aortitis, extramedullary hematopoiesis
Pharmacology
Pegfilgrastim is a PEGylated G-CSF analogue (colony-stimulating factor) that binds specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, commitment, and functional activation; clearance is neutrophil receptor-mediated and nonlinear with dose.
Filgrastim is a recombinant human G-CSF that binds to specific cell surface receptors on hematopoietic cells, stimulating neutrophil progenitor proliferation and differentiation and enhancing end-cell functional activities including phagocytic ability, respiratory burst priming, and antibody-dependent killing.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Neulasta
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Neupogen
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Neulasta
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Neupogen
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Neulasta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Neupogen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NeulastaView full Neulasta profile
NeupogenView full Neupogen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.